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Alzheimer’s disease (AD) is a devastating neurodegenerative condition with significant genetic herita-
bility. Several genes have been implicated in the onset of AD with the apolipoprotein E (APOE) gene being
the strongest single genetic risk loci. Evidence suggests that the effect of APOE alters with age during
disease progression. Here, we aim to investigate the impact of APOE and other variants outside the APOE
region on AD risk in younger and older participants. Using data from both the Alzheimer’s Disease
Neuroimaging Initiative and the UK Biobank, we computed the polygenic risk score of each individual
informed by the latest genetic study from the International Genomics of Alzheimer’s Project. Our analysis
showed that the effect of APOE on the disease risk is greater in younger participants and reduces as
participants’ age increases. Our findings indicate the increased impact of polygenic risk score as par-
ticipants’ age increases. Therefore, AD in older individuals can potentially be triggered by the cumulative
effect of genes which are outside the APOE region.
 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Late-onset Alzheimer’s disease (LOAD) is a devastating neuro-
degenerative condition with evidence suggesting that the patho-
biological process underlying Alzheimer’s disease (AD) may begin
decades before clinical evidence of dementia (Ritchie et al., 2015).
The genetic heritability of LOAD is high (79%); however, the etiology
is driven by a combination of genetic and environmental factors
(Gatz et al., 2006).
A large number of genes have been implicated in the risk of LOAD
(Harold et al., 2009; Jansen et al., 2019; Kunkle et al., 2019; Lambertbtained from the Alzheimer’s
ww.loni.ucla.edu/ADNI). As
d to the design and imple-
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pply/ADNI_Authorship_List.
nstitute at Cardiff University,
(0)2920688429.
tt-Price).
Inc. This is an open access articleet al., 2013; Marioni et al., 2018; Sims et al., 2017) with the apolipo-
protein E (APOE) gene being the strongest genetic risk factor
(Strittmatter et al.,1993).APOE is a cholesterol carrier involved in lipid
transport (Hauser et al., 2011) and brain injury (Houlden and
Greenwood, 2006); it exists in 3 common allelesdε2, ε3, and
ε4dwith a worldwide prevalence of 8.4%, 77.9%, and 13.7%, respec-
tively (Farrer et al., 1997). Numerous studies have demonstrated that
APOE ε4 is associated with an earlier age of disease onset (Blacker
et al., 1997; Bonham et al., 2016; Frisoni et al., 1998; Sando et al.,
2008), longevity (Deelen et al., 2019), and the existence of a gene-
dosage effect between increasing copies of ε4 and lower age of AD
onset (Corder et al., 1993). This age-dependent genetic heterogeneity
was also investigated in theAlzheimer’s DiseaseGenetics Consortium
(ADGC) data (Lo et al., 2019); the authors found moderate genetic
correlation (rg¼ 0.64) between the 2 age groups (60e79years vs. 80þ
years), supporting thepresenceof genetic heterogeneity.Moreover, in
their study, the heritability explained by single-nucleotide poly-
morphisms (SNPs) on chromosome 19, which harbors APOE, was
substantially larger at younger relative to older age.
A number of retrospective studies have shown that the effect of
APOE does not exert its influence with the same magnitude duringunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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(Bickeböller et al., 1997; Davidson et al., 2007). Another study tried
to longitudinally examine the effect of age and APOE ε4 during
progression from normal cognition to AD (Bonham et al., 2016).
They reported that APOE ε4 influences the progression from mild
cognitive impairment to AD in all age groups and the risk varies in
age, reaching its peak between ages 70 and 75 years and decreasing
after the age of 75 years. In addition, in a meta-analysis of APOE
data, authors examined the association between APOE and AD
stratified by age and sex in populations with varying ethnicity and
they reported the diminishing effect of APOE ε4 after the age of 70
years (Farrer et al., 1997). Finally, a different study tested and
confirmed the nonproportional hazard of APOE on ADwith age. The
hazard declined at age 80 years for men and 75 years for women,
indicating that different age compositions of study cohorts can
result in biases on the estimated effect of APOE (Liu and Caselli,
2018).
As prediction algorithms are developed, it will be increasingly
important to identify clinically healthy individuals who are at risk
of AD and develop therapeutic strategies for intervention. Polygenic
risk score (PRS) (Purcell et al., 2009) is a widely used approach
which combines the effect of a large number of variants, whichmay
not reach genome-wide significance individually. AD PRS has been
shown to be strongly associated with disease (Escott-Price et al.,
2015) and explains additional AD risk to that of APOE alone
(Stocker et al., 2018). The analysis of GERAD data by Escott-Price
et al. showed that the effect of PRS is on average slightly lower in
the younger group than in the older group (Escott-Price et al., 2015
Supplementary Table 5). This evidence suggests that APOE may
strongly influence AD risk at younger ages, but as the individuals’
age increases, the effect of APOE is reduced and therefore, other risk
variants start to play a more fundamental role in AD risk. These
variants reside in known AD biological pathways with enrichment
in immune response, lipid processing, cholesterol metabolism,
and endosomal vesicle recycling (Jones et al., 2010; Kunkle et al.,
2019).
In this study, we investigated the effect of APOE and other var-
iants (combined in a genetic score) on the risk of AD and whether
this risk differs with age. We used PRS analysis and we assessed the
relationship between AD and PRS using data from 2 prospective
studies; the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
(Petersen et al., 2010; Weiner et al., 2010) and the UK Biobank
(UKBB) (Sudlow et al., 2015). It should be noted that the ADNI
cohort is older than the UKBB; however, the latter contains parental
AD phenotypes and parental age that were used for the analysis.
Furthermore, the pathway-specific PRSs, for the 9 pathways found
to be significantly associated with AD (Kunkle et al., 2019), were
also investigated to determine whether AD risk at older ages is
altered by a specific biological pathway. Finally, in the UKBB, we
examined whether the ε4’s effect in older patients could be atten-
uated by differential survival because the ε4 allele carriersmay have
shorter life expectancy (Belloy et al., 2019; Deelen et al., 2019), by
exploring the proportion of parents with ages more than and less
than 80 years stratified by the APOE genotype of the participant. The
UKBB participants who are homozygous for these alleles were
chosen, thus making sure that each of their parents have at least
one of the alleles.
2. Materials and methods
2.1. Samples description
ADNI is a longitudinal study that was developed for the early
detection of AD with the use of clinical, genetic, and imaging
data (Petersen et al., 2010). The data were collected from 900participants between ages 55 and 90 years. Initially, participants
were followed for 2 to 3 years with repeated imaging scans and
psychometric measurements (ADNI1). The study was extended
with the addition of new participants (ADNI-GO and ADNI2).
Longitudinal data contained information of clinical assessments
from the first, baseline visit to the latest available visit with
mean follow-up time approximately 5 years. All participants
provided written consent. More information can be found at
http://adni.loni.usc.edu/.
Data were available for 770 individuals from ADNI1, ADNI2, and
ADNI-GO including genetic information and clinical diagnosis. At
the first assessment, 47 individuals were diagnosed with AD, 459
were diagnosed with mild cognitive impairment and 262 were
nondemented/controls. At the latest assessment, 174 individuals
remained stable to AD and 224 remained nondemented/controls.
For this study, we used the latest diagnosis to perform PRS analysis
on AD diagnosed individuals versus controls, excluding partici-
pants who remained stable or progressed to mild cognitive
impairment.
The UKBB is a large prospective cohort of approximately
500,000 individuals from the UK containing extensive phenotypic
and genotypic data which are still being collected (Sudlow et al.,
2015). Participants were recruited between 2006 and 2010 and
were aged 39e72 years. A wealth of lifestyle, sociodemographic,
medical, and family history information were collected through a
computer-based, self-completed questionnaire during the first
assessment visit, along with physical measurements, biological
samples, and cognitive testing. Participants were also interviewed
by a research nurse to determine any diagnosed medical conditions
and their medication use. All participants provided signed consent
and are able to withdraw this consent at any stage. Additional in-
formation can be found at https://www.ukbiobank.ac.uk/.
This study used the UKBB data under UKBB approval for appli-
cation 15175 “Further defining the genetic architecture of Alz-
heimer’s disease”. 364,236 white British and Irish individuals
remained after removing related individuals and those who have
since chosen to withdraw from the study. For the present study,
participants were identified as being diagnosed with AD based on
diagnosis codes across all hospital inpatient records. Diagnoses are
coded according to the International Classification of Diseases
version-10 (ICD-10). The UKBB is a young cohort and none of the
204 AD cases were older than 80 years; thus, family history was
used as a proxy to AD. Self-report of parental history of AD has been
proved to be a valid proxy for an AD genetic study (Marioni et al.,
2018). There were 1554 and 38,417 UKBB participants with family
history of AD for both parents and one parent, respectively.2.2. Genotyping procedures and quality control (QC)
The ADNI samples were genotyped using non-CLIA whole-
genome sequencing and Illumina Omni 2.5 M BeadChip array and
basic QC was performed. Additional QC checks were performed
using PLINK (https://www.cog-genomics.org/plink2/) (Marees
et al., 2018). These included exclusion of SNPs with minor allele
frequency less than 0.01 and genotype missingness greater than
0.02 and SNPs with Hardy-Weinberg equilibrium p-value  106.
After QC, 7,808,548 SNPs were included in the analyses.
The UKBB contains 35,884,914 imputed SNPs. These imputed
data were QCed by removing rare SNPs with minor allele frequency
<0.01, SNPs imputed with poor accuracy (INFO 0.4), SNPs with
posterior probability 0.4, SNPs with missing data proportion
>0.05, and SNPs which violate Hardy-Weinberg equilibriumwith p
< 106. After these QC steps, 7,654,308 SNPs remained for the
analysis.
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2.3.1. Discovery cohort
The PRS (Purcell et al., 2009) combines the effect of a large
number of genetic variants which individually may not reach
genome-wide significance. The summary statistics from the
largest available genome-wide association study (GWAS) on AD
(Kunkle et al., 2019), which is independent from the UKBB sample,
were used to generate genetic scores for both ADNI and UKBB
participants as the weighted sum of the risk alleles. This GWAS is
an extension to the International Genomics of Alzheimer’s Project
(IGAP) data (Lambert et al., 2013); the results were meta-analyzed
to an additional replication set, thus increasing sample size to N ¼
63,926 (stage 1). These summary statistic data were chosen as
they are independent from the UKBB sample, and although the
ADNI data are part of the IGAP study, the overlap does not
significantly affect the PRS prediction (Leonenko et al., 2019).
More specifically, a total of 441 ADNI participants, accounting for
0.7% of the Kunkle et al., 2019 study, were part of the Alzheimer’s
Disease Genetics Consortium (Naj et al., 2011) which was used by
the IGAP study. Leonenko et al performed PRS analysis, adjusting
for this overlap by using 1000 simulations. They modeled the
variation attributed to the exclusion of 441 samples from the
Lambert et al., 2013 summary statistics (0.8%) to account for po-
tential biases and showed that prediction accuracy was not
affected (Leonenko et al., 2019).
2.3.2. Controlling for linkage disequilibrium
The standard PRS approach assumes independence between
SNPs; therefore, data were pruned for linkage disequilibrium (LD).
ADNI data were LD-pruned with PLINK (http://zzz.bwh.harvard.
edu/plink/) (Purcell et al., 2007) by retaining the variant with
the smallest p-value from each LD block and excluding variants
with r2 > 0.1 in 1000-kb window. The imputed UKBB data were
LD-pruned in the same way, using a random sample of 1000 in-
dividuals with “best guess genotypes” computed from allele
“dosages”.
2.3.3. Generation of genetic scores
PLINK was used to construct the PRSs for each participant using
as significance threshold the p-value pT  0.5 because of its pre-
diction accuracy (Escott-Price et al., 2015). 255,026 and 240,984
SNPs were used to derive the PRS excluding APOE, in ADNI and
UKBB, respectively.
2.3.4. Identification of predictors and confounders
In the current analyses, APOE ε2 and ε4 and PRSs without the
APOE region were the main predictors. In both ADNI and the UKBB,
the effects of APOE ε2 and ε4 were estimated in the data using
univariate logistic regression on disease status and were directly
included to the PRS, while excluding the APOE region (chromosome
19:44.4Mb 19:46.5Mb).
The genetic scores were adjusted for age, sex, and principal
components (PCs) and then standardized. In ADNI, the age of the
participants at the last assessment visit was used along with eight
PCs. In the UKBB, the age at the parents’ death or the last recorded
age if they were alive and 15 PCs were used. In both data sets, the
sex of the participants in the study was used. Finally, an additional
analysis was performed using PRSs adjusted for PCs only and
including age and sex as predictors in the regression models as
both variables have predictive value for AD (Escott-Price et al.,
2015). To investigate the contribution of APOE and PRS at the
specific age ranges, individuals were grouped in those of less than
80 years and those of more than 80 years of age.2.3.5. Generation of pathway-specific genetic scores
We produced a pathway-specific PRS in both data sets for each
of the 9 pathways found to be associated with AD (Kunkle et al.,
2019). Genes from the 9 Kunkle pathways were mapped to GEN-
CODE (v29) (Harrow et al., 2012) data, where only known, protein
coding genes were retained. The pathways were defined by all SNPs
which reside between the start and end base position of genes in
the pathway (see Supplementary Table 1). The 9 significantly
associated pathways are protein-lipid complex assembly, regula-
tion of beta-amyloid formation, protein-lipid complex, regulation of
amyloid precursor protein catabolic process, reverse cholesterol
transport, protein-lipid complex subunit organization, plasma li-
poprotein particle assembly, tau protein binding, and activation of
immune response. It should be noted that in contrast to the whole-
genome PRS, pathway-specific analysis models the APOE region
rather than the genotype of the 2 APOE SNPs (rs7412 and rs429358).
The reason for this is to capture additional genetic variation by the
pathways and thus, increase the power. For example, the “activation
of immune response” pathway contains the RELB gene which is in
the APOE region but does not contain the APOE gene.2.4. Statistical analysis
2.4.1. Descriptive analysis
Normally distributed variables were presented using means
with standard deviations.
2.4.2. Association of PRSs with disease status
The association of PRSs with AD status in ADNI was examined
using logistic regression including the following predictors: a) the
direct count of APOE ε4 and ε2 alleles and b) PRS without the APOE
region. A Poisson regression model was used in the UKBB data to
assess the relationship between PRS and parental AD, as the ADwas
coded as 0, 1, 2 indicating the number of parents with the disease,
including the same predictors. A likelihood ratio test was used to
determine whether a) APOE and the PRS excluding APOE both show
an association with AD and b) the PRS excluding APOE explains any
additional variation. Finally, in the UKBB, the same analysis was also
performed for maternal and paternal AD separately using logistic
regression analysis.3. Results
3.1. Association of AD PRS with disease risk stratified by age
Table 1 depicts the association results between AD status and
PRSs in ADNI after adjusting for PCs, participants’ sex and age at
latest assessment visit. A likelihood ratio test indicated that PRS
significantly improves the prediction accuracy of the model in all 3
groups (all, participants younger than 80 years, and participants
older than 80 years) over and above APOE (p ¼ 6.08  1014, p ¼
6.62  105, and p ¼ 1.95  1011, respectively). Examining the
effect sizes of APOE only and PRS excluding the APOE region, the
bAPOE is smaller in the older group (b ¼ 0.78, SE ¼ 0.174, p ¼ 7.08 
106) as compared with the younger group (b ¼ 1.151, SE ¼ 0.194,
p ¼ 3.01  109) in which bPRS is larger (b ¼ 1.456, SE ¼ 0.229, p ¼
1.92  1010 in ages 80 years vs. b ¼ 0.677, SE ¼ 0.169, p ¼ 1.99 
105 in ages <80 years). This suggests that APOE is more important
for AD development in individuals younger than 80 years and above
that age, a polygenic component has a significantly higher contri-
bution over and above APOE alone. As age and sex have predictive
value for AD (Escott-Price et al., 2015), analysis was performed
Table 1
Association results between disease status and polygenic risk scores, in ADNI data set
Phenotype Age N APOE (ε4 þ ε2) PRS (excl. APOE region) (pT  0.5) APOE þ PRS (pT  0.5)
b SE p AUC b SE p AUC p AUC
AD (latest assessment) All AD ¼ 174
NL ¼ 224
0.951 0.126 4.10  1014 0.723 1.066 0.138 1.34  1014 0.747 <1  10350 0.807
<80 AD ¼ 87
NL ¼ 125
1.151 0.194 3.01  109 0.744 0.677 0.169 1.99  105 0.677 1.75  1010 0.798
80 AD ¼ 87
Nl ¼ 99
0.780 0.174 7.08  106 0.667 1.456 0.229 1.92  1010 0.811 7.04  1011 0.825
Logistic regression was performed. The models were adjusted for PCs, participants' age at last assessment and sex.
Genetic variants with p-value pT  0.5 from Kunkle et al. (2019) summary statistics were used to calculate the genetic score.
Key: AD, b, beta coefficient (effect size); Alzheimer's disease; APOE, apolipoprotein E; AUC, area under the curve; excl., excluding; N, sample size; NL, nondemented/controls; p,
p-value; pT, p-value with threshold T  0.5; PRS, polygenic risk score; SE, standard error.
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and PRS, with results remaining the same (results not shown).
The association between AD PRS and parental AD using the
UKBB data is shown in Table 2. Parental AD shows that PRS
excluding APOE is associated with AD over the effect of APOE. When
examining the effect sizes for APOE, it is seen that the effect size is
smaller in the older group (b ¼ 0.208, SE ¼ 0.005, p < 1  10350)
compared with the younger group (b ¼ 0.348, SE ¼ 0.009, p < 1 
10350). The p-values differ between the parental AD age groups;
this is due to the differences in sample size. Therefore, it is appro-
priate to interpret the b values here.
The b values between ADNI and UKBB are comparable, with the
effect of APOE showing consistent results between age groups
across both cohorts. The effect sizes for parental AD in UKBB are
much smaller compared with ADNI because the association be-
tween PRS and a proxy to AD is being considered. In the UKBB, the
effect sizes between the different age groups for PRS excluding
APOE are very similar (all: b ¼ 0.031, <80: b ¼ 0.037, 80: b ¼
0.030).
The parental AD association was surprisingly high when
considering that the individual was used to predict parental
outcome, where only half of the genome is shared among them. The
corresponding results for the models which included age and sex as
predictors were similar (results not shown).
Table 3 displays the effect of APOE and PRS (excluding APOE) on
maternal and paternal AD separately. It can be observed that the
effect sizes in mothers is slightly higher than in fathers and this
effect was consistent for both APOE and PRS excluding APOE. Note
that these effect sizes are from a logistic regression model and are
therefore not directly comparable with the results in Table 2.3.2. Age of parents with the APOE alleles
Theparental ageof theUKBBparticipants rangedbetween60and
107 years. Selecting UKBB participants who are homozygous forTable 2
Association results between parental AD and polygenic risk scores in the UK Biobank da
Phenotype Age N APOE (ε2 þ ε4)
b SE p
Parental AD All BP ¼ 1554 OP ¼ 38,417 NP ¼ 284,110 0.242 0.004 <1 
<80 BP ¼ 326 OP ¼ 10,755
NP ¼ 213,877
0.348 0.009 <1 
80 BP ¼ 1228 OP ¼ 27,662
NP ¼ 70,233
0.208 0.005 <1 
Poisson regression was performed. The models were adjusted for PCs, parental age and
summary statistics were used to calculate the genetic score. The parental age was either
Key: N, sample size; b, beta coefficient (effect size); AD, Alzheimer's disease; APOE, apolipo
neither parent has AD; OP, one parent has AD; p, p-value; pT, p-value with threshold T APOE (ε4ε4, ε3ε3, ε2ε2) alleles, we ensured that each parent had at
least one APOE allele (ε4, ε3, and ε2, respectively). Themothers were
5e6 months older than the fathers within each APOE stratumwhen
their age was last recorded. The last recorded age was similar be-
tween the mothers and the fathers within the 3 APOE groups. The
age at death was about 4 years earlier for the fathers than for the
mothers (see Table 4). Furthermore,we observed a 12-month earlier
age at death for ε4 carriers as compared with ε2 carriers in either
male of female parents, whereas the ε3 carriers were in between.
After splitting the parents into age groups less than and more
than 80 years old (as before), we did not observe a substantial
difference in proportions of mothers or fathers of the UKBB par-
ticipants with either of APOE alleles (Table 5). A slight decrease in
the number of ε4 carriers was observed at the age of 86þ years (see
Supplementary Fig. 1).3.3. Pathway-specific PRS analysis
We have also estimated pathway-specific PRSs for the 9 path-
ways which were associated with AD in Kunkle et al. GWAS (Kunkle
et al., 2019) and examined the association with the risk of AD
phenotypes. All pathway analyses were performed with and
without APOE.
The results can be seen in Fig. 1 and in Supplementary Tables 2
and 4 for ADNI and UKBB data sets, respectively; with SEs and AUC
shown in Supplementary Tables 3 and 5, respectively. All effect
sizes were reduced in the UKBB as compared with ADNI because of
the use of a “proxy” for AD rather than directly assessed AD.
In ADNI data, all pathways in all age groups (all, <80, 80),
except the activation of immune response, were associatedwith the
risk of AD; however, the association was driven by the APOE region
(see Supplementary Tables 2 and 3). Only “protein-lipid complex”
remained significantly associated with AD after removing the APOE
region (b ¼ 0.239, p ¼ 0.021 for all participants and b ¼ 0.310, p ¼
0.043 for participants older than 80 years), with PRS marginallyta
PRS (excl. APOE region) (pT  0.5) APOEþ PRS (pT 0.5)
AUC b SE p AUC p AUC
10350 0.576 0.031 0.005 2.4  1010 0.501 <1  10350 0.573
10350 0.591 0.037 0.009 0.00008 0.511 <1  10350 0.598
10350 0.569 0.030 0.006 1.7  107 0.510 6.0  10314 0.576
participants' sex. Genetic variants with p-value pT  0.5 from Kunkle et al. (2019)
the age at death or the last recorded age if alive.
protein E; AUC, area under the curve; BP, both parents have AD; excl., excluding; NP,
0.5; PRS, polygenic risk score; SE, standard error.
Table 3
Association results between parental AD (split into maternal and paternal AD) and
PRSs in the UK Biobank
Phenotype Age APOE (ε2 þ ε4) PRS (excl. APOE region)
(pT  0.5)
b b
Maternal AD All 0.275 0.035
Paternal AD 0.240 0.031
Maternal AD <80 0.404 0.044
Paternal AD 0.297 0.030
Maternal AD 80 0.273 0.038
Paternal AD 0.225 0.034
Logistic regression was performed. The models were adjusted for PCs, parental age,
and participants' sex. Genetic variants with p-value pT  0.5 from Kunkle et al.
(2019) summary statistics were used to calculate the genetic score. The parental
age was either the age at death or the last recorded age if alive.
Key: b, beta coefficient (effect size); AD, Alzheimer's disease; APOE, apolipoprotein E;
excl., excluding; pT, p-value with threshold T  0.5; PRS, polygenic risk score.
Table 5
Proportion of parents of participants homozygous to APOE alleles in the UKBB







<80 80 <80 80
ε4ε4 0.040 0.036 0.041 0.036
ε3ε3 0.950 0.953 0.949 0.953
ε3ε3 0.010 0.011 0.010 0.011
If parent was alive, the last recorded age was used. Otherwise, the age of death of the
parent was used.
Key: APOE, apolipoprotein E; UKBB, UK Biobank.
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this is consistent with the results presented in a previous study
(Leonenko et al., 2019). As before, the effect sizes for APOE were
larger in the younger group for all 9 pathways compared with the
older group, supporting the increased effect of APOE in younger
ages. Similar results were foundwhen including both age and sex as
predictor variables in the regression models (results not shown).
The “activation of immune response” pathway, which does not
contain APOE gene, showed a clear association in full ADNI sample
(b ¼ 0.279, p ¼ 0.008) and an even stronger association in the older
age group (b ¼ 0.519, p ¼ 0.001), whereas in the younger group the
association was not significant (p ¼ 0.458).
In the UKBB, all pathways showed a significant association with
parental AD for both APOE region and PRS excluding APOE region
except for the “activation of immune response” and “protein-lipid
complex subunit organization” pathway for which the results did
not remain significant after splitting the participants into age
groups (Supplementary Tables 4 and 5). The increased number of
significant results was due to the much larger sample size in the
UKBB compared with ADNI; however, the quantity of significant
results is noteworthy when parental AD is used as a proxy and
therefore effect sizes are small. Again, the effect sizes in parental AD
for APOEwere larger in the younger group compared with the older
group, supporting the increased APOE effect in younger individuals.
The effect sizes for PRS excluding APOE are small, and therefore, it is
difficult to compare them across groups; 4 of the 9 pathways have a
slightly larger effect size in the older group compared with the
younger group. Similar results are shownwhen using age and sex as
predictors in the model.
The “activation of immune response” pathway association in the
UKBB did not show a clear pattern as in the ADNI data. Although in
the group of all parents, the association of this pathway wasTable 4
Parental last recorded age and age at death for participants homozygous to APOE













Mean (sd) Mean (sd) Mean (sd) Mean (sd)
ε4ε4 10,563 78.2 (7.8) 77.9 (7.1) 74.3 (12.7) 70.4 (12.8)
ε3ε3 258,659 79.1 (8.2) 78.4 (7.5) 74.7 (13.2) 70.8 (13.0)
ε2ε2 2808 78.9 (8.3) 78.3 (7.7) 75.4 (12.7) 71.6 (12.6)
If parent was alive, the last recorded agewas used. Otherwise, the age of death of the
parent was used.
Key: APOE, apolipoprotein E; N, number of samples; sd, standard deviation; UKBB,
UK Biobank.statistically significant (b ¼ 0.013, p ¼ 0.0068), when split by age,
the p-values become nonsignificant (p¼ 0.060 and p¼ 0.073, in the
younger and older groups, respectively). The effect sizes of the
parental AD association were similar in all 3 groups (all, <80, 80);
however, these are quite reduced when compared with the ADNI
results. As pointed out earlier, this is likely to be due to the “asso-
ciation via proxy” analyses and as a consequence, the reduced po-
wer of the analyses which in turn potentially explains the absence
of clear pattern, leaving the “activation of immune response”
pathway association results inconclusive (non-replicated) in this
analysis.
Finally, for both ADNI and the UKBB, the b values across both age
groups were compared. There was strong evidence for a difference
in bs between the younger and older groups in all pathways based
on APOE across both data sets, but there was no difference observed
between the bs for each age group for the PRS association excluding
APOE.4. Discussion
It is known that both age and PRS (including APOE) contribute to
liability to AD, but their etiological relationship has not been fully
elucidated. We evaluated an additive model whereby risk of AD
requires less contribution from common SNPs in younger in-
dividuals. Our study benefits from the use of the publicly available
and well-studied ADNI data and the confirmation of results in the
UKBB data using family history as a proxy of AD.
Our study not only shows that the effect of APOE is stronger in
the younger group compared with the older group, aged at least
80 years, but it suggests that the effect of the polygenic component
at the latter age group is significantly greater than APOE alone. This
implies that potentially other/additional biological mechanisms of
AD development can be identified by the polygenic component
over and above APOE in the older individuals. Therefore, the age-
varying effect of APOE and the polygenic component of AD should
be taken into consideration in both clinical and scientific settings.
The complex interplay between the genetic architecture, sex, and
age of patients indicates the incorporation of these risk factors in
both treatment planning and enrollment in clinical trials for iden-
tifying cognitively normal APOE ε4 carriers progressing to AD
(Riedel et al., 2016). The greater effect of PRS in older patients may
aid in stratifying individuals for precision medicines, and in-
dividuals whose AD is predominantly influenced by APOE may
require different treatments to those effected by the polygenic
component of remaining variants.
The work presented in this article supports findings from pre-
vious studies. The heterogeneity of the polygenic architecture
across age in AD was demonstrated by Lo et al. The authors showed
that the heritability explained by chromosome 19 was significantly
larger in the younger participants (Lo et al., 2019). Similar results
have also been presented in previous studies by Escott-Price
Fig. 1. Association of pathway-specific genetic scores (excluding APOE region) with the risk of Alzheimer's disease. Depiction of ADNI (red) and UKBB (blue) data for all individuals
and stratified by age. Bars crossed with a black line depict statistically significant results. Abbreviations: ADNI, Alzheimer's Disease Neuroimaging Initiative; UKBB, UK Biobank. (For
interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
E. Bellou et al. / Neurobiology of Aging 93 (2020) 69e7774(Escott-Price et al., 2015, 2017). Moreover, a number of studies have
suggested differences in magnitude of the effect of APOE during the
entire period of AD risk, with APOE ε4 reaching its peak effect be-
tween the age of 60e79 years (Bickeböller et al., 1997; Bonham
et al., 2016).
Our pathway association results were inconclusive in this
analysis. For both data sets, the effect sizes for APOE were larger in
all 9 pathways in the younger group compared with the older
cohort; whereas, the effect sizes of PRS excluding the APOE region
were larger in 6 of 9 pathways in ADNI and in 4 of 9 pathways in the
UKBB. Furthermore, the “activation of immune response” pathway
association in the UKBB did not show a clear pattern as in the ADNI
data, likely due to the reduced statistical power.
The findings of this study have to be seen in light of some lim-
itations. ADNI is an amnestic clinical population with no reported
comorbidities to be adjusted for in the analysis. Moreover, the
sample size is relatively low, especially when split into age groups.
To address the latter limitation, the UKBB was used for replication
purposes; however, the UKBB data are reliant on a proxy for AD (the
parental AD). Although the analysis by proxy was been used pre-
viously (Marioni et al., 2018), it should be noted that the parental
AD has been grouped by the designers of the UKBB with other
forms of dementia whose prevalence at different age groups could
potentially bias our results. On the same note, the parental AD
phenotype used in the present study combines AD/dementia in
both parents to reduce multiple testing; therefore, parental sex
effects could not be accounted for in our models. We did, however,
investigate maternal and paternal AD separately, which showed
that effect sizes are consistently higher in mothers compared with
fathers. Another potential limitation is the “arbitrary” choice of the
age cutoff used for splitting the subjects into groups. Nevertheless,
these cutoffs seem to be in linewith ages being reported in previous
studies when the effect of APOE started declining. Furthermore, the
decrease in APOE frequency in older ages (Frisoni et al., 1998;
Murman et al., 1996; Sando et al., 2008) could be due to
censoring by the earlier onset of AD in APOE ε4 carriers. We tried to
address this limitation by splitting the parents into age groups less
than and more than 80 years old; however, we did not observemajor difference in the proportion of mothers or fathers on the
UKBB participants with either of APOE alleles. Further investigation
is needed to examine the potential existence of survival biases.
Another plausible explanation could be that APOE ε4 carriers who
have not progressed to cognitive impairment during the risk age
range of 65e75 years, might possess protective genetic or lifestyle
factors that delay that progression.
5. Conclusion
In this study, we emphasize that both APOE and PRS are pre-
dictors of AD risk presenting age-dependent effects on progression
to cognitive decline. We show that the effect of APOE on AD risk is
stronger in individuals with age less than 80 years, whereas PRS
contributes more to the risk of AD development in ages more than
80 years. In the older group, the polygenic risk score has shown to
be the same or higher compared with the younger group. Age-
based risk estimates of the genetic architecture of the disease
could aid in clinical trials of disease-modifying treatments and
personalized medicine once effective therapies are available.
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